Director/PDMR Shareholding
Roquefort Therapeutics plc announced that Interim Managing Director Dr. Darrin Disley purchased 5,000,000 ordinary shares at an average price of 1.70 pence per share, totaling £85,000. This transaction increases his total shareholding to 7,024,196 ordinary shares, representing 4.46% of the company's issued capital. The purchase occurred on November 21, 2025, on the London Stock Exchange.
Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, advises that Dr Darrin Disley, Interim Managing Director, has purchased ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:
| Number of Ordinary Shares Acquired | Average Price Paid per Share | Total Consideration Paid | Number of Ordinary Shares Now Held | % of Company's Issued Capital |
|---|---|---|---|---|
| 5,000,000 | 1.70 pence | £85,000.00 | 7,024,196 | 4.46% |
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Darrin Disley | |
| 2 | Reason for the notification | ||
| a) | Position/status | Interim Managing Director | |
| b) | Initial notification /Amendment | Initial | |
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Purchase of 5,000,000 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 1.70 pence per share | 5,000,000 | ||
| d | Aggregated information - Aggregated volume - Price | - 5,000,000 - 1. 70p | |
| e) | Date of the transactions | 21 November 2025 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.